Prevalence of clinically actionable genotypes and medication exposure of older adults in the community

References

• RellingMVEvansWEPharmacogenomics in the clinicNature2015526757334335026469045
   PubMed Web of Science ®Google Scholar
• DunnenbergerHMCrewsKRHoffmanJMPreemptive clinical pharmacogenetics implementation: current programs in five US medical centersAnnu Rev Pharmacol Toxicol2015558910625292429
   PubMed Web of Science ®Google Scholar
• HagaSBLaPointeNMThe potential impact of pharmacogenetic testing on medication adherencePharmacogenomics J201313648148323999596
   PubMed Web of Science ®Google Scholar
• DaneshiNGrahamMBiswasMMilwardEGene scene-health’s new frontierAust Pharm20153452730
   Google Scholar
• Van DriestSLShiYBowtonEAClinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testingClin Pharmacol Ther201495442343124253661
   PubMed Web of Science ®Google Scholar
• The Pharmacogenomics Knowlegebase (PharmGKB) [homepage on the Internet]2016 Available from: https://www.pharmgkb.org/Accessed February 5, 2016
   Google Scholar
• ChangJSPhamDADangMTLuYVanOsdolSShinJEvaluation of popular drug information resources on clinically useful and actionable pharmacogenomic informationJ Med Libr Assoc20161041586126807054
   PubMed Web of Science ®Google Scholar
• The Pharmacogenomics Knowlegebase (PharmGKB)Clinical Pharmacogenetics Implementation Consortium (CPIC) [webpage on the Internet]2016 Available from: https://www.pharmgkb.org/page/cpicAccessed February 14, 2016
   Google Scholar
• Food and Drug Adminstration (FDA) [homepage on the Internet]2016 Available from: http://www.fda.gov/Accessed February 14, 2016
   Google Scholar
• HagaSBMoaddebJComparison of delivery strategies for pharmacogenetic testing servicesPharmacogenet Genomics201424313914524384556
   PubMed Web of Science ®Google Scholar
• KitzmillerJPGroenDKPhelpsMASadeeWPharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in othersCleve Clin J Med201178424325721460130
   PubMed Web of Science ®Google Scholar
• AdamsSAPetersenCPrecision medicine: opportunities, possibilities, and challenges for patients and providersJ Am Med Inform Assoc201623478779026977101
   PubMed Web of Science ®Google Scholar
• TwiltMPrecision medicine: the new era in medicineEBioMedicine20164242526981568
   PubMed Web of Science ®Google Scholar
• CollinsFSVarmusHA new initiative on precision medicineN Engl J Med2015372979379525635347
   PubMed Web of Science ®Google Scholar
• LanderESCutting the gordian helix – regulating genomic testing in the era of precision medicineN Engl J Med2015372131185118625689017
   PubMed Web of Science ®Google Scholar
• JiYSkierkaJMBlommelJHPreemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascadeJ Mol Diagn201618343844526947514
   PubMed Web of Science ®Google Scholar
• MilwardEADaneshiNJohnstoneDMEmerging real-time technologies in molecular medicine and the evolution of integrated ‘pharmacomics’ approaches to personalized medicine and drug discoveryPharmacol Ther2012136329530422951096
   PubMed Web of Science ®Google Scholar
• ShahandehAJohnstoneDMAtkinsJRAdvantages of array-based technologies for pre-emptive pharmacogenomics testingMicroarrays20165212
   Google Scholar
• MalinovskaABingisserRNickelCHAdverse drug events of older patients presenting in the emergency departmentTher Umsch20157211–12673677 German26654810
   PubMedGoogle Scholar
• ChenTFPharmacist-led home medicines review and residential medication management review: the Australian modelDrugs Aging201633319920426961696
   PubMed Web of Science ®Google Scholar
• FultonMMAllenERPolypharmacy in the elderly: a literature reviewJ Am Acad Nurse Pract200517412313215819637
   PubMedGoogle Scholar
• Suarez-KurtzGClinically actionable genotypes among BraziliansClin Pharmacol Ther2014961252624598719
   PubMed Web of Science ®Google Scholar
• HollidayEGMaguireJMEvansTJAustralian Stroke Genetics Collaborative, International Stroke Genetics Consortium, Wellcome Trust Case Control Consortium 2. Common variants at 6p21.1 are associated with large artery atherosclerotic strokeNat Genet201244101147115122941190
   PubMed Web of Science ®Google Scholar
• McEvoyMSmithWD’EsteCCohort profile: The Hunter Community studyInt J Epidemiol20103961452146320056765
   PubMed Web of Science ®Google Scholar
• HollidayEGAttiaJHancockSGenome-wide association study identifies two novel genomic regions in irritable bowel syndromeAm J Gastroenterol2014109577077224797007
   PubMed Web of Science ®Google Scholar
• BirdwellKADeckerBBarbarinoJMClinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosingClin Pharmacol Ther2015981192425801146
   PubMed Web of Science ®Google Scholar
• JohnsonJAGongLWhirl-CarrilloMClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingClin Pharmacol Ther201190462562921900891
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKSteinCMClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 updateClin Pharmacol Ther201394331732323698643
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKGardnerEEClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapyClin Pharmacol Ther201190232833221716271
   PubMed Web of Science ®Google Scholar
• RellingMVGardnerEESandbornWJClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingClin Pharmacol Ther201189338739121270794
   PubMed Web of Science ®Google Scholar
• RellingMVGardnerEESandbornWJClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 updateClin Pharmacol Ther201393432432523422873
   PubMed Web of Science ®Google Scholar
• WilkeRARamseyLBJohnsonSGClinical Pharmacogenomics Implementation Consortium (CPIC)The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathyClin Pharmacol Ther201292111211722617227
   PubMed Web of Science ®Google Scholar
• OwenRPGongLSagreiyaHKleinTEAltmanRBVKORC1 pharmacogenomics summaryPharmacogenet Genomics2010201064264419940803
   PubMed Web of Science ®Google Scholar
• MegaJLHochholzerWFrelingerALDosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular diseaseJAMA2011306202221222822088980
   PubMed Web of Science ®Google Scholar
• MangraviteLMEngelhardtBEMedinaMWA statin-dependent QTL for GATM expression is associated with statin-induced myopathyNature2013502747137738023995691
   PubMed Web of Science ®Google Scholar
• OggMSBrennanPMeadeTHumphriesSECYP2C9*3 allelic variant and bleeding complicationsLancet199935491841124
   PubMed Web of Science ®Google Scholar
• AblinJCabiliSLagzielAPeretzHWarfarin therapy in a patient homozygous for the CYP2C9 3 alleleIsr Med Assoc J20024213914111875991
   PubMed Web of Science ®Google Scholar
• StewardDJHainingRLHenneKRGenetic association between sensitivity to warfarin and expression of CYP2C9*3Pharmacogenetics1997753613679352571
   PubMedGoogle Scholar
• Food and Drug Ddminstration (FDA) [webpage on the Internet]Coumadin Tablets (Warfarin Sodium Tablets, USP) Crystalline Coumadin for Injection (Warfarin Sodium for Injection, USP)2016 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdfAccessed March 25, 2016
   Google Scholar
• National Prescribing Servive (NPS) Medicinewise [webpage on the Internet]Benefits and risks of statin use in older people2016 Available from: http://www.nps.org.au/topics/ages-life-stages/for-individuals/older-people-and-medicines/for-health-professionals/evidence-and-guidelines/using-statinsAccessed June 26, 2016
   Google Scholar
• National Prescribing Servive (NPS) Medicinewise [webpage on the Internet]Statins revisited: appropriate patient selection is key2016 Available from: http://www.nps.org.au/publications/health-professional/health-news-evidence/2013/statins-absolute-CVD-riskAccessed August 10, 2016
   Google Scholar
• BellGCCrewsKRWilkinsonMRDevelopment and use of active clinical decision support for preemptive pharmacogenomicsJ Am Med Inform Assoc201421e1e93e9923978487
   PubMed Web of Science ®Google Scholar
• VerbeurgtPMamiyaTOesterheldJHow common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotypingPharmacogenomics201415565566524798722
   PubMed Web of Science ®Google Scholar
• Van DriestSLRodenDMResponse to “clinically actionable genotypes among Brazilians”Clin Pharmacol Ther20149612624682028
   PubMed Web of Science ®Google Scholar
• ShahabiPScheinfeldtLBLynchDEAn expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidanceThromb Haemost2016116233734827121899
   PubMed Web of Science ®Google Scholar
• DaneshiNMilwardEAGrahamMAn update on warfarin pharmacogenomics: part 1 of 1Aust Pharm20153455256
   Google Scholar
• DaneshiNMilwardEAGrahamMAn update on warfarin pharmacogenomics: part 2Aust Pharm20153464649
   Google Scholar
• LiXYangJWangXXuQZhangYYinTClinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trialsThromb Res2015135462162925628141
   PubMed Web of Science ®Google Scholar
• SchildcroutJSDennyJCBowtonEOptimizing drug outcomes through pharmacogenetics: a case for preemptive genotypingClin Pharmacol Ther201292223524222739144
   PubMed Web of Science ®Google Scholar